repository
엔테카비어 치료에 부분 바이러스 반응을 보인 환자에서 엔테카비어 유지치료를 한 만성 B형 간염 환자의 경과
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.advisor | 조성원 | - |
| dc.contributor.author | Park, Joo Han | - |
| dc.date.accessioned | 2019-10-21T07:26:28Z | - |
| dc.date.available | 2019-10-21T07:26:28Z | - |
| dc.date.issued | 2016-02 | - |
| dc.identifier.other | 21769 | - |
| dc.identifier.uri | https://dspace.ajou.ac.kr/handle/2018.oak/18779 | - |
| dc.description | 학위논문(박사)--아주대학교 일반대학원 :의학과,2016. 2 | - |
| dc.description.tableofcontents | Ⅰ. INTRODUCTION 1 Ⅱ PATIENTS AND METHODS 3 A. Patients 3 B. Methods 4 C. Statistical Analysis 4 Ⅲ RESULTS 6 Ⅳ. DISCUSSION 11 Ⅴ. CONCLUSION 15 VIII. REFERENCES 16 국문요약 28 | - |
| dc.language.iso | eng | - |
| dc.publisher | The Graduate School, Ajou University | - |
| dc.rights | 아주대학교 논문은 저작권에 의해 보호받습니다. | - |
| dc.title | 엔테카비어 치료에 부분 바이러스 반응을 보인 환자에서 엔테카비어 유지치료를 한 만성 B형 간염 환자의 경과 | - |
| dc.title.alternative | Clinical Course of Partial Virological Responders | - |
| dc.type | Thesis | - |
| dc.contributor.affiliation | 아주대학교 일반대학원 | - |
| dc.contributor.alternativeName | Joo Han Park | - |
| dc.contributor.department | 일반대학원 의학과 | - |
| dc.date.awarded | 2016. 2 | - |
| dc.description.degree | Doctoral | - |
| dc.identifier.localId | 739352 | - |
| dc.identifier.url | http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000021769 | - |
| dc.subject.keyword | entecavir | - |
| dc.subject.keyword | chronic hepatitis B | - |
| dc.subject.keyword | partial virological response | - |
| dc.subject.keyword | tenofovir | - |
| dc.description.alternativeAbstract | Studies about long-term entecavir (ETV) therapy for partial virological response (PVR) are lacking. This study aimed to assess the clinical course of PVR patients receiving ETV therapy and analyze the efficacy of tenofovir (TDF). We retrospectively evaluated 130 patients who showed a PVR to ETV. Among these patients, 102 were nucleot(s)ide analogue (NUC)-naïve and 28 were lamivudine (LAM)-experienced. The cumulative rates of VR were 54.1%, 70.8%, and 83.7% for the NUC-naïve group and 37.0%, 42.8%, and 42.8% for the LAM-experienced group after 24, 36, and 48 months of ETV therapy, respectively (P=0.008). Low HBV DNA level at 12 months (P<0.001) and absence of a LAM treatment history (P =0.031) were significant associated factors for VR. In VR prediction at 36 months of ETV therapy in NUC- naïve patients, HBV DNA level <95 IU/ml at 12 months showed a 92.9% sensitivity and a 78.3% specificity (AUROC, 0.909; P<0.001). ETV resistance did not develop in NUC- naïve patients with HBV DNA levels <95 IU/ml at 12 months. The cumulative probability of VR in patients who switched to or additionally received TDF was 91.3% at 15 months. Prolonged ETV therapy induced a VR without the risk of ETV resistance in NUC-naïve patients with HBV DNA levels <95 IU/ml at 12 months. All patients with LAM-experienced or NUC- naïve with HBV DNA levels ≥ 95 IU/ml at 12 months should be switched to TDF rescue therapy. | - |
- Appears in Collections:
- Graduate School of Ajou University > Department of Medicine > 4. Theses(Ph.D)
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
- STATISTICS
- Total Visit :3,753,334
- Total Download :1,818
- Today View :30,992
